Drug Guide
Ciprofloxacin
Classification
Therapeutic: Antibacterial, fluoroquinolone
Pharmacological: Topoisomerase II (DNA gyrase) inhibitor
FDA Approved Indications
- Bacterial infections caused by susceptible organisms (e.g., urinary tract infections, respiratory tract infections, skin infections, bone and joint infections, gastrointestinal infections)
- Otitis media (Otiprio)
Mechanism of Action
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication, transcription, repair, and recombination, leading to bacterial cell death.
Dosage and Administration
Adult: Typically 250-750 mg every 12 hours orally or IV, depending on infection severity and site.
Pediatric: Generally approved for children ≥1 year for complicated urinary tract infections, pyelonephritis, or inhalational anthrax; dosage varies based on weight and infection.
Geriatric: Adjust dose based on renal function; monitor for increased risk of side effects.
Renal Impairment: Reduce dose and/or extend dosing interval according to creatinine clearance.
Hepatic Impairment: No specific adjustment needed, but monitor hepatic function as necessary.
Pharmacokinetics
Absorption: Well absorbed orally, with bioavailability of approximately 70%.
Distribution: Widely distributed; penetrates tissues and fluids, including cerebrospinal fluid.
Metabolism: Primarily metabolized in the liver; minimal active metabolites.
Excretion: Excreted primarily via kidneys (unchanged) and some via biliary route.
Half Life: Approximately 4 hours in healthy individuals, extended in renal impairment.
Contraindications
- Hypersensitivity to ciprofloxacin or other quinolones.
- History of tendon disorders related to fluoroquinolone use.
Precautions
- Patients with a history of tendon disorders, myasthenia gravis, or seizure disorders.
- Use with caution in elderly, renal impairment, hepatic impairment, or concomitant corticosteroid therapy.
Adverse Reactions - Common
- Nausea (Common)
- Diarrhea (Common)
- Headache (Common)
- Dizziness (Common)
Adverse Reactions - Serious
- Tendon rupture or tendinitis (Rare)
- Peripheral neuropathy (Rare)
- QT prolongation and arrhythmias (Rare)
- Hypersensitivity reactions, including anaphylaxis (Rare)
Drug-Drug Interactions
- Theophylline, caffeine, tizanidine, warfarin, tinidazole, certain corticosteroids (risk of tendon rupture).
Drug-Food Interactions
- Dairy products, calcium-fortified juices, and other calcium-rich foods may impair absorption.
Drug-Herb Interactions
N/ANursing Implications
Assessment: Monitor for signs of infection resolution, adverse reactions, and tendon pain. Assess renal function before and during therapy.
Diagnoses:
- Risk for tendon rupture related to fluoroquinolone therapy.
- Risk for allergic reactions.
Implementation: Administer as prescribed, either orally or IV. Educate patient on hydration to prevent crystalluria.
Evaluation: Monitor for bacterial eradication, adverse reactions, and compliance.
Patient/Family Teaching
- Take medication exactly as prescribed.
- Report any tendon pain, swelling, or inflammation.
- Avoid excessive sun exposure and wear sunscreen.
- Complete the full course even if symptoms improve.
Special Considerations
Black Box Warnings:
- Tendon rupture, tendinitis, peripheral neuropathy, and central nervous system effects.
Genetic Factors: None specifically related to ciprofloxacin.
Lab Test Interference: May interfere with some urine cultures; may cause false-positive urinary glucose tests with some dipstick methods.
Overdose Management
Signs/Symptoms: Nausea, vomiting, dizziness, confusion, seizures.
Treatment: Supportive care; gastric lavage and activated charcoal may be used if ingestion was recent; hemodialysis may be considered in severe renal impairment.
Storage and Handling
Storage: Store at room temperature, 20-25°C (68-77°F).
Stability: Stable for the duration of the expiration date when stored properly.